Rheumatoid Arthritis

SetPoint Medical's FDA-approved device offers a new neuroimmune therapy for rheumatoid arthritis, enhancing treatment options without immune risks.

Stay updated with the latest healthcare breakthroughs, including FDA approvals, clinical trial data, and novel research, in this week's essential news roundup.

Populations most affected by RA are also growing younger and broader since 1990.

The Phase 2b RENOIR trial met its primary endpoint and key secondary endpoints in patients with RA in new 12-week data.

Tocilizumab-anoh will be available in both intravenous and subcutaneous formulations.

Investigators found an incidence of 26.2 severe infections per 100 patient-years with 4 deaths in the study.

Tocilizumab and other biological drugs were particularly efficacious in lowering overall hemostatic potential, mitigating blood clot risks.

Around 37% of those had never used a bDMARD reached sustained DMARD-free remission at 5 years,

Despite improvements in PROs and disease activity, no statistically significant changes have been seen on blood biomarker analysis.

Other recent research presented at ACR 2024 found increased CVD risk with glucocorticosteroid use.

Data from 2 studies presented at ACR 2024 demonstrate the potential of AI to improve access to quality rheumatological assessments.

Over one-third of participants had had inadequate responses or intolerance to at least 3 prior b/tsDMARDs.

People who used GC for over 2 years and 3 years had elevated risks of CVD and infection-related mortality, respectively, that never returned to pre-GC use levels.

While an effective and promising strategy for chronic pain relief, more research on long-term cannabis usage is needed.

Highest responders on DAS28 also had significantly greater decreases in 12-hydroxyeicosatetraenoic than low responders.

Veterans residing in rural areas were only 10% more likely to initiate biologic therapies than those residing in rural areas.

Week 156 efficacy and safety data from the FINCH 4 study are consistent with that seen in FINCH 1, 2, and 3.

Patients exposed to screening were also more likely to receive vaccinations and consult a cardiologist and/or a pneumologist.

Investigators analyzed antibody response after 2 SARS-CoV-2 vaccinations.

The all-optical PAT scanner reduces acquisition time from minutes to seconds and can visualize microvasculature changes to depths approaching 15 mm.

More research is needed to investigate changing trends at presentation and help to inform current treatment strategies.

The data also support the validity of further research into targeting CD-40 signaling in patients with RA not responding to treatment.

In other populations, JAKis demonstrated at least a similar pain benefit to b/tsDMARDs from baseline.

Notably, people with fewer vaccine doses were more likely to experience post-acute sequelae of COVID-19.

Hs-cTnT was found to be associated with a higher risk of MACE and all-cause mortality in a 10-year cohort study.